Insights On Enterprise Solutions

  1. Manufacturing ADCs: Extractables In Single-Use Systems 8/5/2025

    Antibody-drug conjugates offer targeted cancer treatment with reduced toxicity. Discover how single-use technologies simplify ADC manufacturing to ensure safety, flexibility, and efficiency.

  2. Improving U.S. Drug Supply Stability Through Continuous Nanoparticle Processing 8/5/2025

    Learn about a continuous manufacturing platform designed to help overcome challenges in domestic pharmaceutical production, including scale-up barriers and production variability.

  3. Site-Specific Conjugation For Next-Gen ADCs 8/4/2025

    Unlock the full potential of your ADCs with a site-specific conjugation platform that delivers unmatched stability, homogeneity, and therapeutic performance.

  4. Continuous Manufacturing For API Breakthroughs 7/31/2025

    Observe how a compound library, designed for chemical diversity and lead-like properties, uses advanced filtering to improve hit discovery, speed hit-to-lead development, and boost early-stage small molecule drug discovery.

  5. Integrating Cutting-Edge Technologies In Cell Bank Manufacturing 7/31/2025

    Discover how our adoption of a counterflow centrifuge enhances GMP-compliant cell banking through closed-system automation, precision harvesting, and scalable workflows.

  6. Leverage Process Analytical Technology For Developing Novel Conjugates 7/29/2025

    Explore how Process Analytical Technology accelerates novel conjugate development and how PAT is integrated with an ADC platform to enhance efficiency, data quality, and product consistency.

  7. Management Strategies For Adaptive Bio And Single-Use Excellence 7/28/2025

    Single-use technologies (SUTs) bring speed and flexibility to modern biomanufacturing, but realizing their full value requires robust, stage-specific risk management to navigate material, supply chain, and regulatory challenges.

  8. Resilience Capacity Update July 2025: Large Molecule Drug Substance 7/28/2025

    Hear from Evan Pasenello, Head of Commercial Services, about how Resilience can support large molecule programs from early phase through clinical and commercial manufacturing.

  9. Providing Development And Supply Of Life-Changing Medicines 7/28/2025

    Review the strategic application of extensive expertise in microbial systems to meet the increasing demand for novel biologics. Cutting-edge capabilities ensure streamlined development and manufacturing processes.

  10. Cytovance Biologics Capacity Update July 2025: Large Molecule Drug Substance 7/28/2025

    Thomas Kohl, Director of Business Development, shares the company’s microbial and mammalian capabilities and their available capacity. Cytovance delivers ingenuity end-to-end to both large pharma and biotech clients alike.